Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 599 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Fred Hutchinson Cancer Center Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

NCT00987480
View directory record Official record
Conditions
Aplastic Anemia, Leukemia, Myelodysplastic Syndrome
Interventions
Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine., CliniMACS device
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Jul 23, 2026, 7:38 AM EDT
Not yet recruiting Phase 2 Interventional

Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases

NCT07660783
View directory record Official record
Conditions
Bone Marrow Failure, Hemoglobinopathies, Primary Immune Deficiency (PID), Autoimmune Cytopenia, Immune Dysregulation, Hemophagocytic Lymphohistiocytosis (HLH), Non Malignant Disorders
Interventions
ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1Phase 2 Interventional

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

NCT00093366
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
etanercept, arsenic trioxide
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer

NCT04211766
View directory record Official record
Conditions
Healthy Subject
Interventions
Dietary Fiber, Fish Oil, Comparator
Dietary Supplement · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated Phase 1 Interventional Results available

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT02706405
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Interventions
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Cyclophosphamide, Durvalumab, Fludarabine
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Glasdegib for Chronic Graft-Versus-Host Disease

NCT04111497
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Fasciitis
Interventions
Glasdegib
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Jul 23, 2026, 7:38 AM EDT
Recruiting No phase listed Observational

EDRN Prostate MRI Biomarker Study

NCT03784924
View directory record Official record
Conditions
PSA, Prostate Cancer
Interventions
MRI prostate
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Male only
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Enhancing Connections Program in Improving Family Adjustment in Patients With Incurable Cancer

NCT03049397
View directory record Official record
Conditions
Advanced Malignant Neoplasm
Interventions
Communication Intervention, Questionnaire Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
5 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

NCT00107523
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, idarubicin, pravastatin
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Jul 23, 2026, 7:38 AM EDT
Completed No phase listed Observational Results available

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

NCT01929408
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
12
States / cities
Stanford, California • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1Phase 2 Interventional

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

NCT00052520
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
therapeutic allogeneic lymphocytes, aldesleukin, peripheral blood stem cell transplantation, allogeneic bone marrow transplantation, laboratory biomarker analysis, gene expression analysis, immunologic technique, flow cytometry, polymerase chain reaction, cytogenetic analysis, staining method
Biological · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Trial of a Telephone Weight Loss, Nutrition, Exercise Study

NCT03738540
View directory record Official record
Conditions
Weight Loss, Weight, Body
Interventions
TALK study group, TALK control group
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Jul 23, 2026, 7:38 AM EDT
Withdrawn Phase 1 Interventional

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

NCT05228249
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Loncastuximab Tesirine, Melphalan
Procedure · Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Jul 23, 2026, 7:38 AM EDT
Active, not recruiting Not applicable Interventional

Multilevel Interventions to Increase Adherence to Lung Cancer Screening

NCT05747443
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Screening
Interventions
Stepped Reminders, Patient Education
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years to 78 Years
Enrollment
1,837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jul 23, 2026, 7:38 AM EDT
Not yet recruiting Not applicable Interventional

Effect of Meal Timing During Adjuvant Treatment for Cancer

NCT07524218
View directory record Official record
Conditions
Cancer
Interventions
Time-restricted eating, Questionnaire Administration, Biospecimen Collection, Health coaching
Behavioral · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 7:38 AM EDT
Recruiting Phase 2 Interventional

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

NCT06013423
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide, Cyclosporine, Diagnostic Imaging, Echocardiography, Fludarabine Phosphate, Multigated Acquisition Scan, Mycophenolate Mofetil, Survey Administration, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated Not applicable Interventional

Reducing Insulin, Growth Hormones, and Tumors

NCT03785808
View directory record Official record
Conditions
Diet Modification, Lung Cancer
Interventions
Special Diet Therapy (low-carb), Special Diet Therapy (low-fat), Special Diet Therapy (USDA control)
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission

NCT00045435
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia
Interventions
nonmyeloablative allogeneic hematopoietic stem cell transplantation, fludarabine phosphate, total-body irradiation, cyclosporine, mycophenolate mofetil, peripheral blood stem cell transplantation
Procedure · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
55 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma

NCT00313625
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
busulfan, melphalan, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

PATH Partnering to Achieve Tobacco-free Health

NCT01533974
View directory record Official record
Conditions
Smoking Cessation
Interventions
Acceptance & Commitment Therapy (ACT), Cognitive Behavioral Therapy (CBT)
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Not applicable Interventional

Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors

NCT03523195
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Cancer Survivor, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Sedentary Lifestyle
Interventions
Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis, Monitoring Device, Questionnaire Administration, Physical Performance Testing
Behavioral · Other · Device
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1Phase 2 Interventional

Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease

NCT00118326
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma
Interventions
filgrastim, allogeneic bone marrow transplantation
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Jul 23, 2026, 7:38 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

EQQUAL-NM for the Promotion of Smoking Cessation in Sexual and Gender Minority Young Adults in New Mexico

NCT06386432
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Smartphone App-delivered Smoking Cessation Intervention, Health Promotion and Education, Biospecimen Collection, Questionnaire Administration
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Phase 2 Seattle Dietary Biomarkers Development Center

NCT06656338
View directory record Official record
Conditions
Healthy Adults
Interventions
Higher HEI-2020 diet followed by lower HEI-2020 diet, Lower HEI-2020 diet followed by higher HEI-2020 diet
Other
Lead sponsor
Marian Neuhouser
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 7:38 AM EDT